# A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)

> **NCT01335607** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Samatasvir tablet
- **DRUG:** Samatasvir capsule

## Key facts

- **NCT ID:** NCT01335607
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01335607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01335607, "A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01335607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*